Developing clear and structured monitoring strategies that minimise risks and optimise compliance success rates.

Last year at the Pharma Compliance Europe 2014 event, Karolina Czernicka-Kuhl,  Head of Legal and Compliance, Novo Nordisk, gave the presentation “Developing clear and structured monitoring strategies that minimise risks and optimise compliance success rates.”

Download and learn:

  • Why monitoring?
  • What should be monitored?
  • How to monitor (who should monitor)?
  • Benefits and costs

Download Presentation

Found this interesting? You might also be interested in our Pharma Compliance Europe 2015 event, taking place 7-8 October in London. Find out more

Leave a Reply

Your email address will not be published. Required fields are marked *